RxDoctor Payments DataLook up a doctor →

Paul Hendrix, MD

Internal Medicine · Tulsa, OKNPI 1306848692

Payments from drug & device makers

$12,903in general payments, 2019–2025

Across 801 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$954
  • Lilly USA, LLC$930
  • Pfizer$912
  • Amgen$649
  • plus $5K from 46 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)184$2,312
AstraZeneca98$2,266
Novo Nordisk51$954
Lilly USA, LLC60$930
Pfizer58$912
Amgen(2 entities)40$649
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$536
Currax Pharmaceuticals LLC34$485
Boehringer Ingelheim31$466
Merck35$439
Takeda Pharmaceuticals U.S.A., Inc.22$378
Johnson & Johnson20$303
Bayer16$268
Astellas Pharma US Inc14$236
Amarin Pharma, Inc.11$186
Exact Sciences6$122
Azurity Pharmaceuticals, Inc.6$99
Corium, LLC5$92
Kowa Pharmaceuticals America, Inc.6$92
Intra-sana Laboratories5$87
Sumitomo Pharma America, Inc.4$86
Dexcom, Inc.4$82
Eisai Inc.4$63
Clarus Therapeutics Inc.4$60
GSK4$59
Abbott3$57
Genentech USA, Inc.3$55
Cormedix Inc.2$48
Edwards Lifesciences2$48
Ironwood Pharmaceuticals, Inc3$45
Phathom Pharmaceuticals, Inc.3$42
Althera Pharmaceuticals LLC2$42
Axsome Therapeutics, Inc.2$37
Nabriva Therapeutics, PLC2$36
Amneal Pharmaceuticals LLC1$32
Therapeuticsmd, Inc.2$28
Biohaven Pharmaceutical Holding Company Ltd.2$26
Nalpropion Pharmaceuticals LLC2$25
Vivus LLC1$20
OPKO Pharmaceuticals, LLC1$20
Regeneron Healthcare Solutions, Inc.1$20
IBSA Pharma Inc.1$18
Ascend Therapeutics US, LLC1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Sunovion Pharmaceuticals Inc.1$16
Radius Health, Inc.1$15
Scilex Pharmaceuticals Inc.1$15
Novartis1$14
Biogen1$14
Biohaven Pharmaceuticals, Inc.1$12
Alfasigma USA, Inc.1$11
Avanir Pharmaceuticals, Inc.1$11

How this compares

$12,903 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma →

Medicare billing

Part B allowed, 2024
$194,202
Medicare patients
560
Services billed
20,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tulsa

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →